Citius Oncology, Inc.
CTOR
$0.94
$0.011.17%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 94.17% | 526.80% | 32.84% | -32.34% | 14.56% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 110.11% | 305.30% | 43.81% | -29.35% | 6.83% |
| Operating Income | -79.90% | -282.98% | 17.87% | 29.35% | -6.83% |
| Income Before Tax | -76.88% | -259.25% | 17.59% | 29.04% | -10.30% |
| Income Tax Expenses | -140.61% | -187.51% | 0.00% | 83.47% | 83.47% |
| Earnings from Continuing Operations | -66.18% | -243.99% | 16.90% | 26.66% | -12.51% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -66.18% | -243.99% | 16.90% | 26.66% | -12.51% |
| EBIT | -79.90% | -282.98% | 17.87% | 29.35% | -6.83% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -10.27% | -146.07% | 32.01% | 34.80% | -6.08% |
| Normalized Basic EPS | -17.26% | -156.81% | 32.56% | 36.96% | -3.96% |
| EPS Diluted | -10.27% | -146.07% | 32.01% | 34.80% | -6.08% |
| Normalized Diluted EPS | -17.26% | -156.81% | 32.56% | 36.96% | -3.96% |
| Average Basic Shares Outstanding | 50.79% | 39.80% | 22.24% | 12.48% | 6.00% |
| Average Diluted Shares Outstanding | 50.79% | 39.80% | 22.24% | 12.48% | 6.00% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |